Sujaatha Narayanan - Concepedia

Author

Sujaatha Narayanan

University of British Columbia

Also Known As

S Narayanan, S. Narayanan, Sathya Narayanan, Sujaatha Narayanan, Yasser Abou Mourad

108

Publications

510

Citations

H-Index

Concepts

All Affiliations

University of British Columbia BC Cancer Agency Vancouver General Hospital Leukemia & Lymphoma Society of Canada Canada's Michael Smith Genome Sciences Centre

About

Sujaatha Narayanan is an author at University of British Columbia specializing in medicine, cell transplantation, and transplantation.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	235
2	Health Sciences	5	5	134
3	Blood Transplantation	2	2	65
4	Allergy	1	1	50
5	Cell Biology	1	1	19

Sujaatha Narayanan

Publications

434

Citations

H-Index

Page 1

	Year	Citations
Rituximab is effective in the management of refractory autoimmune cytopenias occurring after allogeneic stem cell transplantation Kavita Raj, Sujaatha Narayanan, B. Augustson, Bone Marrow Transplantation Cell TherapyTransplantationAllergyAutoimmune DiseaseStem Cell Transplantation	2004	50
Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation Haowei Sun, Kerry J. Savage, Aly Karsan, Clinical Lymphoma Myeloma & Leukemia Non-hodgkin LymphomasLymphoid NeoplasiaHematological MalignancyTransplantationConcurrent Myc	2015	44
PROTON MR SPECTROSCOPY IN MULTIPLE SCLEROSIS Douglas L. Arnold, Nicola De Stefano, Sujaatha Narayanan, Neuroimaging Clinics of North America	2000	37
Novel agents improve survival of transplant patients with multiple myeloma including those with high-risk disease defined by early relapse (<12 months) Christopher P. Venner, Joseph M. Connors, Heather J. Sutherland, Leukemia & lymphoma/Leukemia and lymphoma Transplantation MedicineImmunologyPathologyImmunotherapyMyeloid Neoplasia	2010	36
Response to Tyrosine Kinase Inhibitor Therapy in Patients with Chronic Myelogenous Leukemia Relapsing in Chronic and Advanced Phase Following Allogeneic Hematopoietic Stem Cell Transplantation Matthew P.F. Wright, John D. Shepherd, Michael J. Barnett, Biology of Blood and Marrow Transplantation	2009	33
Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors Anish Nair, Michael J. Barnett, Raewyn Broady, Biology of Blood and Marrow Transplantation Cell TherapyMixed-phenotype Acute LeukemiaPathologyMyeloid NeoplasiaHematological Malignancy	2015	29
CLIC-01: Manufacture and distribution of non-cryopreserved CAR-T cells for patients with CD19 positive hematologic malignancies Natasha Kekre, Kevin A. Hay, John R. Webb, Frontiers in Immunology	2022	29
Allogeneic haematopoietic stem cell transplantation for chronic lymphocytic leukaemia: outcome in a 20‐year cohort Cynthia L. Toze, Chinmay B. Dalal, Thomas J. Nevill, British Journal of Haematology	2012	25
Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience Musa Alzahrani, Maryse Power, Yasser Abou Mourad, Biology of Blood and Marrow Transplantation Hematological MalignancyPrognostic EvaluationTransplantationMarrow TransplantationOncology	2018	23
Excellent real‐world outcomes of adults with Burkitt lymphoma treated with <scp>CODOX</scp>‐M/<scp>IVAC</scp> plus or minus rituximab Katie Y. Zhu, Kevin Song, Joseph M. Connors, British Journal of Haematology	2018	23

Page 1